Kia ora Jodie

Thank you for your request for information, received by Pharmac on 17 April 2024. Your request has been received and logged. Our reference number for your request is: 2023-24-170.

As required under the Official Information Act 1982, we will respond to your request within 20 working days. You should receive a response on or before 16 May 2024.

If a large amount of information has been requested, we may need to extend this date (this is provided for in section 15A of the Act). We will advise you if such an extension is necessary.

Please feel free to contact us if you require any further assistance.

Ngâ mihi,

Katy Carlson (she/her) | Government Services Advisor
___________________________________________________________________
Te Pâtaka Whaioranga – Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
P: 0800 660 050 |http://www.pharmac.govt.nz/

-----Original Message-----
From: J Bruning <[FOI #26458 email]>
Sent: Wednesday, April 17, 2024 11:23 AM
To: Web Enquiry <[email address]>
Subject: Official Information request - Immunosuppressed/diabetic/cancer populations - common associated conditions.

[You don't often get email from [FOI #26458 email]. Learn why this is important at https://aka.ms/LearnAboutSenderIdentific... ]

Dear Pharmaceutical Management Agency,

According to the 2023 Year in Review report, Gross spend on immunosuppressants, increased 11% from 2020-2023, from $280.3 million to $311.3 million.
Gross spend on chemotherapeutic agents increased 48% from $103.9 million to $154.2 million.
Gross spend on diabetes medication increased 93% from $75.8 million to $146.6 million.
https://pharmac.govt.nz/assets/Year-in-R...

It is unclear how Pharmac analyses the costs of comorbidity to assess the total cost of illness in New Zealand.
Please share with New Zealand public, the most up to date advice, reports, and information advising:
a. For people prescribed immunosuppressants, the most predominant associated health conditions (in data/percentages).
b. For people prescribed chemotherapeutic agents, data on types and prevalence of associated comorbid health conditions (in data/percentages) and data on costs of medicines commonly co-prescribed.
c. For people prescribed diabetes medication, data on types and prevalence of associated comorbid health conditions (in data/percentages) and data on costs of medicines commonly co-prescribed.
d. General information held by Pharmac on the costs of multimorbidity and/or metabolic syndrome.

Thank you

Yours faithfully,

Jodie Bruning.

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #26458 email]

Is [PHARMAC request email] the wrong address for Official Information requests to Pharmaceutical Management Agency? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.
This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.

hide quoted sections

Kia ora Jodie,

Please find attached a response to your Official Information Act request of 17 April 2024.

Thank you
Government Services
___________________________________________________________________
Te Pātaka Whaioranga | Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
http://www.pharmac.govt.nz/

-----Original Message-----
From: J Bruning <[FOI #26458 email]>
Sent: Wednesday, April 17, 2024 11:23 AM
To: Web Enquiry <[email address]>
Subject: Official Information request - Immunosuppressed/diabetic/cancer populations - common associated conditions.

[You don't often get email from [FOI #26458 email]. Learn why this is important at https://aka.ms/LearnAboutSenderIdentific... ]

Dear Pharmaceutical Management Agency,

According to the 2023 Year in Review report, Gross spend on immunosuppressants, increased 11% from 2020-2023, from $280.3 million to $311.3 million.
Gross spend on chemotherapeutic agents increased 48% from $103.9 million to $154.2 million.
Gross spend on diabetes medication increased 93% from $75.8 million to $146.6 million.
https://pharmac.govt.nz/assets/Year-in-R...

It is unclear how Pharmac analyses the costs of comorbidity to assess the total cost of illness in New Zealand.
Please share with New Zealand public, the most up to date advice, reports, and information advising:
a. For people prescribed immunosuppressants, the most predominant associated health conditions (in data/percentages).
b. For people prescribed chemotherapeutic agents, data on types and prevalence of associated comorbid health conditions (in data/percentages) and data on costs of medicines commonly co-prescribed.
c. For people prescribed diabetes medication, data on types and prevalence of associated comorbid health conditions (in data/percentages) and data on costs of medicines commonly co-prescribed.
d. General information held by Pharmac on the costs of multimorbidity and/or metabolic syndrome.

Thank you

Yours faithfully,

Jodie Bruning.

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #26458 email]

Is [PHARMAC request email] the wrong address for Official Information requests to Pharmaceutical Management Agency? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.

hide quoted sections